Navigation Links
Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2
Date:5/23/2013

gía de la compañía, y el impacto de los datos clínicos y otros datos técnicos. Las declaraciones prospectivas se basan en las actuales expectativas de la dirección y están sujetas a riesgos e incertidumbres que pueden causar que los resultados de Volcano difieran material y adversamente de las declaraciones contenidas aquí. Algunos de los posibles riesgos e incertidumbres que podrían causar que los resultados reales difieran incluyen el ritmo y extensión de la adopción de mercado de los productos y tecnologías de la compañía, resultados clínicos no esperados, incluyendo datos clínicos nuevos no esperados y análisis adicionales de datos clínicos existentes, acciones regulatorias no esperadas o retrasos o regulaciones gubernamentales, la capacidad de la compañía para mantener u obtener patentes o protección de la propiedad intelectual, competencia en general, presiones de la industria en general o de precios públicos, temas no previstos de fabricación, estrategias de crecimiento, la oportunidad y logro de hitos de desarrollo de productos, el resultado de litigios, el impacto y beneficios del desarrollo de mercado, introducciones de productos, nuevos datos no esperados, problemas de seguridad y técnicos, las condiciones del mercado y otros riesgos inherentes al desarrollo y comercialización de dispositivos médicos. Estos y otros riesgos e incertidumbres se describen totalmente en los archivos de Volcano presentados a la Comisión de Bolsa y Valores, incluyendo nuestro informe trimestral reciente en Formulario 10-Q. No debería depositarse una confianza indebida en las declaraciones prospectivas que se refieren solo a la fecha en que se realizaron. Volcano no asume obligación alguna de actualizar las declaraciones prospectivas para reflejar nueva información, eventos o circunstancias después de la fecha en que se r
'/>"/>
SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
2. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
3. Volcano Corporation Presentation At Jefferies Conference To Be Webcast
4. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
5. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
9. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
10. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
(Date:7/10/2014)... July 10, 2014  Decision Resources Group finds ... disease (ID) specialists are willing to prescribe Durata,s ... for use as OPAT, approximately two-thirds of the ... to their hospital inpatients. However, our findings indicate ... are initiated on OPAT following hospital discharge, and ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
(Date:7/11/2014)... 11, 2014 Alliance for Cancer ... non-profit dedicated exclusively to cell and gene therapies ... has joined the organization as Senior Development Officer. ... deep experience securing gifts and addressing influential donors. ... Giving Director for NewYork Presbyterian Hospital/Columbia University Medical ...
(Date:7/11/2014)... 2014 Global enterprises today are shifting ... day-to-day management activities. Managed services offer these global enterprises ... economic slowdown resulted into rising operational costs to companies. ... considered to be the global market driver for expanding ... global managed services market is estimated to grow from ...
(Date:7/11/2014)... July 11, 2014 Presently, disposable medical ... healthcare equipment and supplies segment. During the past two ... steady growth (on an average 12.5% per year), primarily ... settings. Currently, the US is the largest market for ... share of 40%. The second position is held by ...
(Date:7/11/2014)... Researchers from The Miriam Hospital have found that ... significantly higher rates of smoking than those without ... less likely to attempt quitting than those without ... be sufficient for this population. The study and ... print in the American Journal of Public ...
(Date:7/11/2014)... has found that organic foods and crops have ... including more antioxidants and fewer, less frequent pesticide ... 343 peer-reviewed publications comparing the nutritional quality and ... fruits, vegetables, and grains. The study team applied ... and non-organic foods. , "Science marches on," ...
Breaking Medicine News(10 mins):Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Miriam Hospital study examines smoking prevalence 2Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3
... Enjoy the Freedom to Breathe, Event to Raise Awareness of Benefits ... ... Hundreds of attendees,of this week,s 2007 National Conference on Tobacco or ... Thursday outside,the Minneapolis Convention Center to raise awareness about the benefits ...
... Open Access: freely available for anyone to read, ... the authorship is properly attributed. , This week ... that aim to highlight the profound influence of ... of Science Editors Global Theme Issue on Poverty ...
... Care Pipeline Offers State-of-the-art Treatment, MEMPHIS, ... leader in cancer care, announced today the ... square foot, state-of-the art,facility is being opened ... provide ,western-style, comprehensive cancer care. Shanghai,represents the ...
... of gloss, depth of image, and ... MANSFIELD, Texas, Oct. 22 Solvay Engineered Polymers,Inc., ... use in the,production of extruded sheet. The new ... acrylic layer onto a substrate of thermoplastic,polyolefin (TPO) ...
... and NEW YORK, Oct. 22 ,Genzyme Corporation (Nasdaq: ... BIVN ),announced this afternoon that Bioenvision stockholders have ... Genzyme at a reconvened special,shareholder meeting in New ... have now ceased trading and the company will,be ...
... ,Super Bug, Other Biological ... ... dozens of cases of MRSA,the drug-resistant staph bacterium, are being reported ... student, some,school districts are taking the proactive step of bringing in ...
Cached Medicine News:Health News:Hundreds to Gather for Rally in Celebration of Right to Breathe Clean Air 2Health News:Which intervention would do the most to improve the health of the extreme poor? 2Health News:Which intervention would do the most to improve the health of the extreme poor? 3Health News:Which intervention would do the most to improve the health of the extreme poor? 4Health News:Which intervention would do the most to improve the health of the extreme poor? 5Health News:West Clinic Continues Expansion Into Asian Market With Opening of Shanghai Cancer Center 2Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 2Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 3Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 4Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 2Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 3Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4Health News:MARCOR Responds to Deadly MRSA Outbreak 2
Curved shafts with micro Pierse type tips. Flat open serrated handle with dull finish....
Straight shafts with 0.1 mm Pierse tips. Flat smooth handle with dull finish....
Colibri style 0.1 mm Pierse tips. Flat smooth handle with dull finish....
The Elschnig teeth of this forceps are ideal for grasping sclera during suturing. Delicate tying platform handles the finest suture material. 0.12 mm, 1 x 2 teeth....
Medicine Products: